Topical loteprednol may aid in the treatment of MGD

Article

Patients with moderate and severe meibomian gland dysfunction (MGD) may benefit from topical loteprednol etabonate and eyelid scrubs with warm compresses, according to researchers in South Korea.

Patients with moderate and severe meibomian gland dysfunction (MGD) may benefit from topical loteprednol etabonate and eyelid scrubs with warm compresses, according to researchers in South Korea. They found the treatment well-tolerated and efficacious, with beneficial effects particularly manifesting after 1 month.

In a study published online in the American Journal of Ophthalmology, the researchers conducted a randomized, controlled trial of two groups of patients with moderate and severe MGD. Group I (34 eyes) received topical loteprednol etabonate and eyelid scrubs with warm compresses; Group II (36 patients) used eyelid scrubs and warm compresses alone. The patients were assessed before treatment and at 1 and 2 months of treatment.

In Group I, the researchers found significant decreases in the levels of interleukin (IL)-6, IL-8, and IL-1β; the researchers cited a remarkable observed decrease in these cytokines between pre-treatment measurements and measurements taken after 1 month of treatment. Patients in Group II experienced significant decreases in the levels of IL-6 and IL-8.

Compared with the patients in Group II, patients in Group I showed superior improvements in the clinical outcomes measured, including tear film break-up time, corneal and conjunctival fluorescein staining, and meibum quality after 1 month of treatment.

In addition, patients in Group I displayed a more remarkable improvement in meibomian gland expressibility and MGD stage reduction than those in Group II.

To read an abstract of the study, click here.

Related Videos
A screenshot of Dr Filomena Ribeiro, president of the ESCRS
Ramin Tadayoni, MD, speaks with Sheryl Stevenson
Jennifer I. Lim, MD, FARVO, FASRS, Director of Retina Service, University of Illinois at Chicago
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center
Carl D. Regillo, MD, FACS, FASRS, Chief of Retina Service, Wills Eye Hospital, Philadelphia, PA
Arshad Khanani, MD, MA FASRS, on a virtual call
Penny A Asbell, MD, FACS speaks at the 2023 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.